Hemopurifier Plus Pembrolizumab in Head and Neck Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is an Early Feasibility Study (EFS) investigating the use of the Hemopurifier to clear
immunosuppressive exosomes in combination with pembrolizumab (Keytruda) in the front line
setting, in patients with advanced and/or metastatic squamous cell carcinoma of the head and
neck.